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Persistent viruses disseminate from immune hosts. They must therefore resist neutralization by
antibody. Murine gammaherpesvirus-68 (MHV-68) represents an accessible model with which to
addresshowresistance toneutralizationisachievedand howovercoming itmightimproveinfection
control. The MHV-68 glycoprotein B (gB), like that of other herpesviruses, is a virion protein
that is essential for infectivity. As such, it presents a potential neutralization target. In order to test
whether virus-induced antibodies reduce virion infectivity by binding to gB, monoclonal antibodies
(mAbs) were derived from MHV-68-infected mice. gB-speciﬁc mAbs were common, but only
an IgM speciﬁc for the gB N terminus reduced virion infectivity signiﬁcantly. It inhibited MHV-68
entry into BHK-21 cells at a post-binding step that was linked closely to membrane fusion.
Reducing the mAb to IgM monomers compromised neutralization severely, suggesting that a
pentameric structure was crucial to its function. Antibody treatment never blocked BHK-21 cell
infection completely and blocked the infection of NMuMG epithelial cells hardly at all. Virions
saturated with antibody also remained infectious to mice. Thus, the MHV-68 gB presents at best a
very difﬁcult target for antibody-mediated neutralization.
INTRODUCTION
Herpesviruses are among the most successful of all
vertebrate parasites. They robustly establish persistent,
productive infections of immunocompetent hosts. This is
achieved without generalized immunosuppression, toler-
ance of viral gene products or signiﬁcant viral antigenic
variation. For example, the murine cytomegalovirus
glycoprotein B (gB) is immunogenic, yet the region
associated with neutralization is antigenically conserved in
ﬁeld isolates (Xu et al., 1996). Thus, infected individuals
simultaneously produce virus-speciﬁc antibodies and
secrete infectious virions. They also remain susceptible to
reinfection (Klein, 1989; Boppana et al., 2001; Sitki-Green
et al., 2003; Gorman et al., 2006). A major infection-control
challenge is to work out why established antibody responses
fail to stop herpesviruses trafﬁcking in or out of their hosts.
Many persistent viruses resist neutralization by antibody.
Human immunodeﬁciency virus (HIV) (Pantophlet &
Burton, 2006) demonstrates the difﬁculty of neutralizing
even virions with just one glycoprotein species.
Herpesviruses – which generally express at least 10 different
virion glycoproteins – are more transmissible than HIV and
mustthereforeresistneutralizationatleastaswell.However,
immune sera appear to neutralize herpesviruses in vitro
(Fenner et al., 1974). Some antibodies may therefore be
capable, if present in sufﬁcient amounts, of neutralizing
herpesvirusesinvivo.Immuneseraarenotoriouslycomplex.
Monoclonal antibodies (mAbs) provide a simpler way to
identify key neutralization targets, and neutralizing mAbs
derived from virus carriers are of particular interest. They
represent responses that could potentially be boosted by
vaccination to reduce long-term shedding of infectious
virions.
Our focus is on the gammaherpesviruses. The major
neutralization target deﬁned for the archetypal gammaher-
pesvirus, Epstein–Barr virus (EBV), is gp350 (Thorley-
Lawson & Poodry, 1982). However, gp350 is redundant for
epithelial-cell infection (Janz et al., 2000), raising questions
as to the in vivo signiﬁcance of this neutralization. Partial
neutralization of Kaposi’s sarcoma-associated herpesvirus
(KSHV) has been reported for rabbit sera raised against
recombinant gH, gL (Naranatt et al., 2002) or gB (Akula
et al., 2002). Whether these speciﬁcities account for the
in vitro neutralizing activity of human immune sera
(Dialyna et al., 2004) is unknown. Analyses of EBV and
KSHV neutralization are hindered by the difﬁculty of
growing these viruses in vitro and by the limited
opportunities for manipulation in vivo. Murine gamma-
herpesvirus-68 (MHV-68) is a natural parasite of yellow-
necked mice (Kozuch et al., 1993) that addresses some of
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ventional mice also appear to behave as natural MHV-68
hosts, in that infection persists without causing disease,
unless there is immune suppression. After intranasal
infection, MHV-68 replicates lytically in respiratory epithe-
lial cells and establishes latency in memory B cells (Sunil-
Chandra et al., 1992a; Flan ˜o et al., 2002). Immune sera from
infected mice (Stevenson & Doherty, 1998, 1999) or from
rabbits immunized with whole virus (Sunil-Chandra et al.,
1992b), gp150 (Stewart et al., 1999) or ORF4 (Gangappa
etal.,2002)haveallbeenreportedtoneutralizeMHV-68for
ﬁbroblast infection. However, neither ORF4 (Adler et al.,
2000) nor gp150 (de Lima et al., 2004) is essential for
infectivity. Comparison with other herpesviruses, as well as
the general principle that robust neutralization should
inactivate essential proteins, would suggest gH/gL and gB as
more likely targets (Moorman et al., 2004; Songet al.,2005).
We recently derived several gH/gL-speciﬁc neutralizing
mAbs from MHV-68-infected mice (Gill et al., 2006). We
did not ﬁnd neutralizing mAbs speciﬁc for ORF4 or gp150.
Surprisingly, we also failed to identify neutralizing mAbs
speciﬁc for gB, even though gB is often reported as a
herpesvirus neutralization target (Cranage et al., 1986;
Pereira et al., 1989; Takeda et al., 1996; Akula et al., 2002;
Wang et al., 2003b). gB is generally essential for membrane
fusion(Turneretal.,1998;Pertel,2002;Lopper&Compton,
2004). It often also has a receptor-binding/signalling
function. For example, the human cytomegalovirus gB
binds to the epidermal growth factor (EGF) receptor (Wang
et al., 2003b) and the KSHV gB binds to integrins (Akula
et al., 2002). Blocking either interaction inhibits infection
at a post-binding step. The MHV-68 gB has a consensus
heparin-binding sequence equivalent to that of the KSHV
gB (Akula et al., 2001), but lacks the RGD motif essential for
KSHV integrin binding (Wang et al., 2003a). Whether gB
makes a signiﬁcant contribution to MHV-68 cell binding is
not known.
A possible reason for our previous failure to identify gB-
speciﬁc, MHV-68-neutralizing mAbs is that we focused on
only the most effective mAbs, regardless of their speciﬁcity.
We have now looked more explicitly for gB-directed
neutralization. This search led to the isolation of a gB-
speciﬁc mAb capable of blocking infection at a post-binding
step. However, gB-directed neutralization was far from
universally effective. We present here an analysis of how a
gB-speciﬁc neutralizing antibody interacts with MHV-68
virions.
METHODS
Mice. Female BALB/c mice were purchased from Harlan UK Ltd,
housed in the Cambridge University Department of Pathology and
infected intranasally with MHV-68 when 6–12 weeks old. For mAb
production, three mice were given an intraperitoneal virus boost at
3–6 months post-infection. Spleens were harvested and pooled
3 days later. To recover infectious virus, lungs were removed at
7 days post-infection, freeze–thawed and broken up by Dounce
homogenization. Large debris was removed by centrifugation (200 g,
1 min) and homogenates were stored at 270uC.
Viruses. Fluorescent-tagged MHV-68 was made by attaching
enhanced green ﬂuorescent protein (EGFP) to the C terminus of gM
(May et al., 2005a). The gM coding sequence (genomic co-ordinates
56950–55799) was ampliﬁed (Hi-Fidelity PCR kit; Roche
Diagnostics) by using an XhoI-restricted 59 primer (59-TATCT-
CGAGATGCCTGCCCTTAAAGTGCCA-39) and a BamHI-restricted
39 primer (59-TTTGGATCCTAGTTCATCTTCTGATTCTGTCTC-
39) and cloned into the BamHI and XhoI sites of pEGFP-N3
(Clontech). This placed the EGFP coding sequence downstream of
and in frame with that of gM. Genomic co-ordinates 55800–54649
of MHV-68 were then ampliﬁed with an AﬂII-restricted 59
primer (59-AAACTTAAGAGCTCTAGCCTTTGGATAAGATGTGA-
A-39) and a NotI-restricted 39 primer (59-AAAGCGGCCGCAA-
ACATTTTATTAAAGTAATTAAAGCAAAT-39) and cloned into the
AﬂII and NotI sites of pEGFP-N3-gM. The EGFP coding sequence
with its 1150 bp MHV-68 genomic ﬂanks was excised by using a
BglII site in the pEGFP-N3 polylinker and the SacI site in the AﬂII-
restricted PCR primer, ligated into the BamHI and SacI sites of
Table 1. mAbs used in this study
mAb Target Isotype Neutralization Reference
15G9 gB* IgM Yes This study
2C10 gB IgM Yes This study
10C11 gB IgM Yes This study
9H9 gB IgM Yes This study
9F2 gB IgM Yes This study
2H4 gB IgM Yes This study
1C12 gB IgG2a No This study
4D11 gB IgG2a No This study
T7H9 gB IgG2a No Lopes et al. (2004)
1A12 gB IgG2a No This study
11G9 gB IgG2a No This study
1E12 gB IgG2a No This study
15B7 gB IgG2a No This study
12A9 gB IgG1 No This study
4A1 gB IgG1 No This study
5B1 gB IgG1 No This study
7E5 gH/gL IgG2a Yes Gill et al. (2006)
T2C12 gH/gL IgG2a Yes Gill et al. (2006)
T6G10 ORF4D IgM No This study
16D2 ORF4 IgG2a No Gill et al. (2006)
LSD1 gp150d IgM No This study
T1A1 gp150 IgG2a No de Lima et al. (2004)
LSB11 gp150 IgG1 No This study
3F7 gN IgG2a No May et al. (2005a)
12B8 ORF65§ IgG2a No This study
*mAbs recognized CHO-K1 cells expressing the extracellular domain
of gB with a GPI anchor (Lopes et al., 2004).
DmAbs recognized CHO-K1 cells stably transfected with ORF4, and
BHK-21 cells infected with wild-type, but not ORF4-deﬁcient,
MHV-68 (Adler et al., 2000).
dmAbs recognized L929 cells stably transfected with gp150, and
BHK-21 cells infected with wild-type, but not gp150-deﬁcient,
MHV-68 (de Lima et al., 2004).
§See Fig. 4(a–c).
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artiﬁcial chromosome (BAC) by standard protocols (Adler et al.,
2000). Infectious virus was reconstituted by transfecting BAC DNA
into BHK-21 cells with Fugene 6 (Roche Diagnostics). The loxP-
ﬂanked BAC cassette was removed by passaging virus through NIH-
3T3-CRE cells (Stevenson et al., 2002). Virus stocks were grown in
BHK-21 cells (Coleman et al., 2003).
Plasmids. The coding sequences for aa 25–423, 25–65 or 428–698
of the mature gB extracellular domain were cloned as EcoRI/XhoI-
or EcoRI/SalI-restricted PCR products (Phusion DNA polymerase;
New England Biolabs) into the EcoRI and XhoI sites of pGEX-4T-1
(Amersham Biosciences). They were then expressed as fusions with
N-terminal glutathione S-transferase (GST) by transformation into
Escherichia coli BL21 and induction with IPTG (Boname et al.,
2005). The bacteria were lysed in 150 mM NaCl, 50 mM Tris
(pH 7?4), 5 mM EDTA, 1% Triton X-100 with Complete Protease
inhibitors (Roche Diagnostics), 1 mM PMSF and 1 mM N-ethylma-
leimide. GST fusion proteins were recovered by adsorption to glu-
tathione–Sepharose beads (Amersham Biosciences), washed three
times in lysis buffer and eluted with an excess of free glutathione.
The MHV-68 ORF65 coding sequence was expressed as a GST
fusion protein in a similar way. We have previously expressed the
gB extracellular domain (genomic co-ordinates 16526–18617) as a
glycosylphosphatidylinositol (GPI)-linked membrane protein (Lopes
et al., 2004). Amino acid residues 1–423 of gB were expressed simi-
larly by amplifying the relevant region of the MHV-68 genome with
59 and 39 primers containing AvrII and NotI restriction sites, respec-
tively, and cloning the PCR product into the XbaI/NotI sites of
pBRAD. The coding sequence for aa 428–698 of gB was ampliﬁed by
using a blunt-ended 59 primer and a NotI-restricted 39 primer. This
PCR product was ligated into pBRAD-gB cut with NotI and SnaBI.
This left in place the gB coding sequence up to aa 22, and the 59
primer included the coding sequence for aa 23–25. Thus, aa
428–698 were linked to the normal gB signal sequence (residues
1–24) plus residue 25.
Cells and antibodies. BHK-21 cells, NIH-3T3 cells, NIH-3T3-
CRE cells (Stevenson et al., 2002), NS0 cells, MRC-5 cells, 293T cells,
NMuMG cells and murine embryonic ﬁbroblasts (MEFs) were pro-
pagated in Dulbecco’s modiﬁed Eagle’s medium supplemented with
2 mM glutamine, 100 U penicillin ml
21, 100 mg streptomycin ml
21,
50 mM 2-mercaptoethanol and 10% fetal calf serum (May et al.,
2005b). B-cell hybridomas were generated by fusing splenocytes with
NS0 cells using PEG 1500 (Roche Diagnostics). Hybrids were cul-
tured on irradiated MRC-5 feeder cells and selected with azaserine
(1 mgm l
21)/hypoxanthine (100 mM) (Gill et al., 2006). mAbs were
concentrated from hybridoma supernatants by ammonium sulfate
precipitation, dialysed against PBS and quantiﬁed by ELISA against
mouse immunoglobulin standards. Isotyping was by ELISA using
isotype-speciﬁc capture and/or detection antibodies (Sigma). Where
indicated, ammonium sulfate-precipitated mAbs were biotinylated
with N-hydroxybiotin–succinamide ester (Pierce) and then dialysed
against PBS to remove free biotin. All of the mAbs used are listed in
Table 1. A biotinylated goat anti-GST polyclonal antibody (pAb)
was purchased from Santa Cruz Biotechnology.
Virus assays. Infectious virus was titrated by plaque assay
(Coleman et al., 2003). Virus preparations were centrifuged (200 g,
1 min) prior to neutralization assays to remove any large debris.
Neutralization was tested by incubating virus with antibody for 1 h
at 37uC before adding the virus/antibody mixtures to cells for a
further 2 h. The cells were then overlaid with 0?3% carboxymethyl-
cellulose and the cell monolayers were ﬁxed and stained for plaque
counting after a further 4–5 days. For binding/entry assays, virus
was incubated with cells at 4 or 37uC, then washed in PBS (pH 7?4)
to remove unbound virus or in isotonic citrate buffer (pH 3?0) to
remove any virus that had not penetrated the plasma membrane or
been endocytosed. Infection was quantiﬁed by plaque assay, and
virion uptake by immunoﬂuorescence or ﬂow cytometry.
Immunoblotting. Virions were recovered from infected-cell super-
natants by ultracentrifugation (35000 g, 90 min) and denatured by
heating in 0?1% SDS/1% 2-mercaptoethanol (95uC, 5min). Where
indicated, the denatured samples were digested with endoglycosidase
H or protein N-glycanase F (New England Biolabs) according to the
manufacturer’s instructions. All samples were then mixed with an
equal volume of 26 Laemmli’s buffer, denatured by heating (95uC,
2 min), resolved by SDS-PAGE and transferred to PVDF membranes
(Boname et al., 2004). Membranes were blocked by pre-incubation
in PBS/0?1% Tween 20, 10% non-fat milk, and then incubated with
MHV-68-speciﬁc mAbs or biotinylated goat anti-GST pAb, followed
by horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG
pAb (Dako Corporation) or HRP-conjugated streptavidin, and ECL
substrate development (Amersham Biosciences).
Immunoﬂuorescence. MHV-68-infected BHK-21 cells or trans-
fected 293T cells were ﬁxed in 4% paraformaldehyde for 30 min,
Fig. 1. Identiﬁcation of gB-speciﬁc neutralizing mAbs. MHV-68 (100 p.f.u.) was incubated with gB-speciﬁc mAb
supernatants (2 ml) and then added to BHK-21 cell monolayers. Plaques were counted 4 days later and are expressed
relative to the number of plaques with virus plus no antibody. The neutralizing gH/gL-speciﬁc IgG2a mAbs 7E5 and T2C12
were used as positive controls.
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MHV-68 gB resists neutralization by mAbsFig. 2. Recognition of N-terminal and C-terminal gB extracellular-domain fragments by virus-neutralizing IgMs. (a) 293T cells
were left untransfected (UT) or transfected with a GPI-linked form of the gB extracellular domain (gB) or its N-terminal 423 aa
(gB-N). Forty-eight hours later, all cells were stained with gB-speciﬁc mAbs as indicated. Each number is the percentage of
cells in the positively staining region. 2H4, 15G9, 2C10, 10C11, 9H9 and 9F2 are all gB-speciﬁc neutralizing IgMs. 5B1 is a
gB-speciﬁc non-neutralizing mAb that does not recognize gB-N. (b) 293T cells were transfected as in (a), but with an
additional control of GPI-linked aa 423–698 of gB (gB-C), which was not detectable at the cell surface. After 48 h, the cells
were ﬁxed, permeabilized and stained with the gB-speciﬁc neutralizing mAb 2C10 or the gB-C-speciﬁc non-neutralizing mAb
4D11. The other neutralizing mAbs gave equivalent staining to 2C10. (c) MHV-68 virions were lysed, denatured and digested
with no enzyme (Nil), endoglycosidase H (EH) or protein N-glycanase F (PF) to remove N-linked glycans. All samples were
then resolved by SDS-PAGE and immunoblotted as indicated. T7H9 and 4D11 are speciﬁc for gB-N and gB-C, respectively.
(d) gB fragments corresponding to its N-terminal and C-terminal extracellular-domain cleavage products were expressed as
GST fusion proteins in E. coli. GST alone and GST fused to aa 21–151 of gp150 were used as speciﬁcity controls.
Denatured proteins were immunoblotted for GST with a polyclonal serum or for gB with mAb 2C10. All of the gB-speciﬁc
neutralizing IgMs gave the same results. (e) The N-terminal 40 aa of the mature gB extracellular domain were expressed fused
to GST and immunoblotted with gB-speciﬁc IgM mAbs as in (d). Again, all of the gB-speciﬁc IgMs were indistinguishable.
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speciﬁc mAbs (May et al., 2005b). Fluorescent-tagged virions were
visualized directly. For simultaneous staining of viral capsid and gly-
coprotein antigens, we used an IgG2a mAb against ORF65 (12B8)
and an IgG1 mAb against gp150 (LSB11). Binding was then detected
with Alexa 488-coupled IgG1-speciﬁc and Alexa 568-coupled IgG2a-
speciﬁc pAb (Invitrogen). In some experiments, nuclei were counter-
stained with DAPI (4,6-diamidino-2-phenylindole). Fluorescence
was visualized with a Leica confocal microscope.
Flow cytometry. Cells exposed to EGFP
+ viruses were analysed
directly for green-channel ﬂuorescence. Transfected cells were trypsi-
nized and stained with mAbs as described previously (Stevenson
et al., 2000). Detection was with ﬂuorescein isothiocyanate-conju-
gated rabbit anti-mouse IgG pAb (DakoCytomation). Cells were
analysed on a FACSort analyser by using CellQuest software (Becton
Dickinson).
RESULTS
Identiﬁcation of gB-speciﬁc neutralizing mAbs
We previously derived seven MHV-68 gB-speciﬁc mAbs to
identify gBasavirioncomponent (Lopes etal.,2004). These
mAbs recognized virus-infected cells, but did not neutralize
infectivity. In three subsequent fusions, we recovered
another 75 gB-speciﬁc mAbs from MHV-68-infected
mice. Again, none gave signiﬁcant neutralization – 2 ml
hybridoma supernatant reduced the infectivity of 100 p.f.u.
MHV-68 by <50% (data not shown). All gB-speciﬁc mAbs
were selected for their capacity to recognize unﬁxed CHO
cells expressing a GPI-linked form of the gB extracellular
domain (Lopes et al., 2004). These cells appear to reproduce
every gB epitope that is available on MHV-68-infected
BHK-21 cell surfaces (P. G. Stevenson, unpublished data).
In a ﬁnal fusion, seven of 41 gB-speciﬁc mAbs gave >50%
neutralization (Fig. 1).
The MHV-68-speciﬁc antibody response takes at least
3 months to reach a plateau level (Stevenson & Doherty,
1998), so all mAbs werederivedfrom mice at least3 months
post-infection. Typically, 90–95% were IgGs. However, all
of the gB-speciﬁc neutralizing mAbs were IgMs (Fig. 1).
Neutralizing mAbs target the gB N-terminal
domain
The MHV-68 gB, like that of cytomegalovirus (Vey et al.,
1995), is cleaved by a furin-like enzyme as virions leave the
cell (Lopes et al., 2004). The predicted recognition site for
furinintheMHV-68 gBisataa424–427.Inordertoidentify
which fragment of the gB extracellular domain contained its
neutralizationepitope(s),wetested theneutralizing IgMs for
their recognition of each fragment expressed separately as a
GPI-linked protein (Fig. 2a). All of the neutralizing IgMs
recognized the N-terminal gB fragment (aa 1–423) on
transfected cell surfaces. None recognized the C-terminal
part of the gB extracellular domain (aa 428–698), which did
not reach the cell surface, but was detectable in the
endoplasmic reticulum of transfected cells by the non-
neutralizing IgG mAb 4D11 (Fig. 2b). mAb 5B1 (Fig. 2a) is
equivalent in speciﬁcity to 4D11.
The neutralizing IgMs also immunoblotted gB in glycanase-
treated virion lysates (Fig. 2c). Their epitope(s) were
therefore independent of gB folding, disulﬁde bonding or
N-linked glycosylation. The minor 50 and 75 kDa bands
detected by each IgM were probably non-speciﬁc, as they
were detected by neither the gB-N-speciﬁc mAb T7H9 nor
the gB-C-speciﬁc mAb 4D11. mAbs 16D2 (anti-ORF4) and
Fig. 3. Mutual inhibition of binding between the gB-speciﬁc
neutralizing IgM mAbs. MHV-68-infected BHK-21 cells (2 p.f.u.
per cell, 18 h) were pre-incubated with gB-speciﬁc hybridoma
supernatants, followed by a biotinylated gB-speciﬁc IgM as
indicated. Binding of the biotinylated mAb to infected-cell sur-
faces was detected with ﬂuorescent streptavidin and ﬂow cyto-
metry. An example assay is shown in (a), with mAb LSD1 as a
non-gB-reactive isotype control, mAb 1A12 as a gB-reactive,
non-neutralizing control and 15G9 as the biotinylated mAb.
Summarized data for gB-speciﬁc mAbs are shown in (b).
Blocking of biotinylated mAb staining is indicated by +;n o
effect on biotinylated mAb staining is shown by ”.
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The IgMs also recognized N-terminal gB fused to GST and
expressedinE.coli(Fig. 2d).Theirepitope(s)weretherefore
independentofO-linkedglycosylation.Thepredictedsizeof
the fusion protein was 74 kDa. The smaller products
recognized on immunoblots were probably formed by
degradationofthefusionproteinfromitsC-terminalgBend
rather than its N-terminal GST end, as they were recovered
with glutathione-coated beads and the smallest product was
still detected by an anti-GST pAb (Fig. 2d). The molecular
mass of GST is 26 kDa, so only a very small fragment of gB
appearedtobe required forrecognition. Thiswasconﬁrmed
by the recognition of a GST fusion protein containing only
the N-terminal 40 aa of the mature gB (Fig. 2e).
The neutralizing IgMs also inhibited each other’s binding to
infected-cell surfaces (Fig. 3) and were indistinguishable by
SDS-PAGE or immuno-electrophoresis (data not shown).
We concluded that they were probably all derived from the
same B-cell clone, presumably from just one mouse. The
clone must have been large, as we were able to sample it
multiple times from the pool of all gB-speciﬁc mAbs.
However, our failureto identify anequivalentclone–or any
other gB-speciﬁc neutralizing mAb – in four other fusions
indicated that it was only rarely a major component of the
response to MHV-68 infection.
gB-directed neutralization operates at a post-
binding entry step
We used immunoﬂuorescence and EGFP virus tagging to
track MHV-68 entry into BHK-21 cells. We ﬁrst derived a
mAb speciﬁc for the MHV-68 ORF65 gene product –
predicted to be a small capsid component(Fig. 4a–c). mAbs
from MHV-68-infected mice were screened by ELISA for
speciﬁc recognition of ORF65 fused to GST (Fig. 4a). The
GST–ORF65-speciﬁcmAb12B8stainedthenucleiofMHV-
68-infected BHK-21 cells (Fig. 4b) and immunoblotted an
18–22 kDa protein in virion lysates (Fig. 4c) (the predicted
molecular mass of the ORF65 gene product is 20 kDa).
The capsids of intact virions are surrounded by tegument
and are therefore unlikely to be accessible to antibody.
Accordingly, capsids were not seen immediately after
adding virions to cells, but became visible when time was
allowed for virion uncoating (Fig. 4d). When virions were
pre-treated with the gB-speciﬁc neutralizing mAbs 15G9 or
2C10, gp150 staining was not impaired (Fig. 4e). Cell
binding was therefore maintained. However, viral capsids
failed to appear in signiﬁcant numbers.
MHV-68 infects BHK-21 cells via endocytosis (Gill et al.,
2006). This is seen as a redistribution of incoming virion
glycoproteins at 37uC (Fig. 4d). The redistribution still
occurred when virions were pre-treated with a gB-speciﬁc
neutralizing antibody (Fig. 4f), implying that the virions
hadstillbeenendocytosed.Neutralizationwasevidentinthe
same experiment from a reduction in nuclear green
ﬂuorescence, i.e. a reduction in viral EGFP expression
from the BAC cassette in newly infected cells. gB-directed
neutralization therefore appeared to block a process linked
closely to membrane fusion.
Flow cytometry using EGFP-tagged MHV-68 conﬁrmed
more quantitatively that gB-directed neutralization had
little effect on cell binding (Fig. 5). For these experiments,
we tagged the MHV-68 gM with C-terminal EGFP. The
MHV-68 gN and gM form a disulﬁde-linked heterodimer
(May et al., 2005a). Thus, gM–EGFP ﬂuorescence co-
localized with gN-speciﬁc staining (Fig. 5a). At early times
after infection, incoming virions were visible as ﬂuorescent
dots on the plasma membrane that couldalso be detected by
ﬂow cytometry (Fig. 5b). Virus neutralization by immune
serum correlated with a considerable drop in cellular EGFP
ﬂuorescence (Fig. 5c). Equivalent neutralization by anti-
gH/gL or anti-gB mAbs gavelittle reduction in ﬂuorescence.
We consider a reduction to 25% EGFP
+ cells as non-
speciﬁc, as this was seen with the non-neutralizing mAb
T1A1. mAb 2H4 gave a marginally greater reduction.
However, this has to be compared with a reduction to 5%
EGFP
+ cells for equivalent neutralization by immune
serum. It is possible – even likely – that the MHV-68 gB has
a cellular ligand, but reduced cell binding did not appear to
explain gB-directed neutralization.
Comparison of gB-directed and gH/gL-directed
neutralization
gH/gL-directed MHV-68 neutralization notably requires
relatively high levels of antibody (Gill et al., 2006). By
Fig. 4. gB-directed neutralization blocks infection at a post-binding step. (a) ELISA plates were coated with no antigen, GST
or GST fused to ORF65 and then incubated with mAb 12B8 or control mAb. Bound antibody was detected with alkaline
phosphatase-coupled goat anti-mouse Ig and nitrophenylphosphate substrate. Mean±SD values are shown. (b) BHK-21 cells
were infected (Inf) or not (UI) with MHV-68 (2 p.f.u. per cell, 18 h) and then ﬁxed, permeabilized and stained with mAb 12B8.
Nuclei were counterstained with DAPI. (c) BHK-21 cells were either left uninfected (Nil) or infected with MHV-68 (2 p.f.u. per
cell, 18 h) (Vir). Cells were then lysed with 0?1% SDS, sonicated and immunoblotted with mAb 12B8. (d) BHK-21 cells were
exposed to MHV-68 for 2 h at 46C, then washed with PBS and either ﬁxed (t=0) or incubated ﬁrst for a further 2 h at 376C
(t=120). All cells were stained for gp150 with mAb LSB11 and for ORF65 with mAb 12B8. Nuclei were counterstained with
DAPI. (e) MHV-68 was pre-treated with mAbs as indicated, then added to cells (3 p.f.u. per cell, 376C). After 2 h, the cells
were washed, ﬁxed, permeabilized and stained as in (d). (f) MHV-68 was pre-treated or not with mAb 10C11 for 1 h, then
incubated with cells for 4 h at either 4 or 376C before PBS washing. All cells were then ﬁxed, permeabilized and stained for
gp150 with mAb LSB11. Arrows indicate nuclear green ﬂuorescence coming from viral EGFP expression in newly infected
cells.
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MHV-68 gB resists neutralization by mAbscomparison, gB-directed neutralization gave a rapid reduc-
tion in infectivity as antibody levels increased, but less
complete neutralization when antibody was saturating
(Fig. 6a) [note that Fig. 6(a) plots antibody concentration
on a logarithmic scale]. Similar results were obtained with
MHV-68 recovered directly from the lungs of infected mice
(Fig. 6b).Anti-gBoranti-gH/gLmAbsneutralizedMHV-68
less well for MEF infection than for BHK-21 cell infection
(Fig. 6c) and failed to inhibit MHV-68 infection of
NMuMG epithelial cells (Fig. 6d). Virions coated comple-
tely with apparently neutralizing antibodies therefore still
infected some cell types with a relatively high probability.
When anti-gB and anti-gH/gL mAbs were combined, the
neutralization achieved was greater than with either alone
(Fig. 6e). We tested in vivo neutralization with single or
combined neutralizing mAbs by adding saturating amounts
of gB-speciﬁc and gH/gL-speciﬁc neutralizing mAbs to
MHV-68 virions and then infecting mice intranasally with
the equivalent of 1 p.f.u. each (Fig. 6f). All of the mice
became infected. Thus, at least some cells in the respiratory
tract remained susceptible to infection by antibody-coated
virions, i.e. NMuMG cells represented in vivo neutralization
more faithfully than BHK-21 cells.
High antibody avidity is crucial for gB-directed
neutralization
Secreted, pentameric IgM has a valency ﬁve times that of
IgG. This high avidity helps to preserve suboptimal binding
interactions inearly antibody responses.However, MHV-68
does not induce sizeable long-term IgM responses – the
virus is essentially a T cell-dependent antigen that elicits IgG
(Stevenson & Doherty, 1999; Sangster et al., 2000). The
selection of a rare IgM mAb by the gB-directed neutraliza-
tion screen therefore suggested that high avidity was
functionally important. To test this, we reduced the gB-
speciﬁc IgMs to monomers with 10 mM dithiothreitol
(Fig. 7a). This compromised neutralization severely
(Fig. 7b). By contrast, there was little effect on virus
neutralization by the gH/gL-speciﬁc IgG2a mAb 7E5. The
IgM monomers still bound to infected-cell surfaces
(Fig. 7c). They gave less ﬂuorescence than the pentamers,
but this presumably reﬂected that pentamers contain ﬁve
times as many binding sites for secondary antibody
detection. Thebindingofmonomersandpentamerstitrated
similarly. Thus, although the pentameric structure of the
IgMs was important for neutralization, it was not required
for extracellular virion binding. It seemed more likely that
high avidity helped to maintain virion binding after
endocytosis.
DISCUSSION
In order to establish the susceptibility of gammaherpesvirus
virions toneutralization outside apurelyinvitrocontext, we
have begun to analyse the glycoprotein-speciﬁc antibody
response of MHV-68-infected mice. The MHV-68 gB is an
obviouscandidate for neutralization:itis a highly conserved
Fig. 5. EGFP virus tagging reveals no obvious link between
gB-directed neutralization and cell binding. (a) BHK-21 cells
were infected (18 h, 2 p.f.u. per cell) with MHV-68 gM–EGFP
(green) and then stained for gN with mAb 3F7. Nuclei were
counterstained with DAPI. (b) BHK-21 cells were exposed to
MHV-68 gM–EGFP (5 p.f.u. per cell, 1 h, 376C) and washed
with PBS. EGFP ﬂuorescence was visualized by confocal
microscopy or ﬂow cytometry. (c) MHV-68 gM–EGFP was
mixed with MHV-68-immune mouse serum (Imm), a gH/gL-spe-
ciﬁc neutralizing mAb (7E5), a gB-speciﬁc neutralizing mAb
(2H4) or a gp150-speciﬁc non-neutralizing mAb (T1A1). Each
virus/antibody mixture was incubated with BHK-21 cells for
parallel ﬂow cytometry and plaque assay. The dashed lines indi-
cate the limit of non-speciﬁc reductions in infectivity or EGFP
transfer, as deﬁned by the non-neutralizing mAb T1A1.
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L. Gillet and othersvirion protein that is essential for infectivity and is
equivalent to a reported neutralization target on other
herpesviruses. However, although gB-speciﬁc mAbs could
readily be derived, gB-speciﬁc neutralizing mAbs were rare.
Even the most effective mAb reduced infectivity to a
threshold value rather than to zero, was cell-type speciﬁc in
its potency and was critically dependent on high avidity for
even modest neutralization. Most tellingly, mAb combina-
tions that appeared to neutralize quite well in vitro failed to
prevent infection in vivo.
Fig. 6. Neutralization of MHV-68 infectivity for different cell types with gB-speciﬁc and gH/gL-speciﬁc mAbs. (a) Wild-type
MHV-68, grown in BHK-21 cells, was incubated with neutralizing mAbs against gB (15G9, 10C11) or gH/gL (7E5, T2C12),
or non-neutralizing mAbs against gB (T7H9) or gp150 (T1A1). Each virus/antibody mixture was then titrated by plaque assay.
(b) Wild-type MHV-68 was recovered from the lungs of infected mice and tested for neutralization with different mAbs as in
(a). (c) The same virus/antibody mixtures as in (a) were titrated on MEFs rather than BHK-21 cells. (d) Virus was incubated
with antibody (1 h, 376C) and then split for parallel titration on NMuMG epithelial cells, NIH-3T3 ﬁbroblasts and BHK-21
ﬁbroblasts. (e) Wild-type MHV-68 (200 p.f.u.) was incubated with 30 mg neutralizing mAbs against gH/gL (T2C12), gB
(2C10) or both (T2C12/2C10). Each virus/antibody mixture was then titrated by plaque assay on BHK-21 cells or MEFs. (f)
Wild-type MHV-68 (100 p.f.u.), grown in BHK-21 cells, was incubated with 100 mg neutralizing mAbs against gH/gL
(T2C12), gB (2C10), both (T2C12/2C10) or no antibody (Controls). Each of ﬁve mice were infected intranasally with 1/100
of virus/antibody mixture (1 p.f.u.). Lungs were removed 6 days later and titrated for infectious virus by plaque assay.
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MHV-68 gB resists neutralization by mAbsFig. 7. Disulﬁde bond reduction impairs gB-directed, IgM-mediated neutralization. (a) The gB-speciﬁc IgM mAbs 2H4 and
2C10 or the gH/gL-speciﬁc mAb 7E5 were reduced with 10 mM dithiothreitol (DTT) or not (UR), then denatured and
immunoblotted for mouse Ig. (b) MHV-68 was incubated with equivalent reduced (DTT) or unreduced (UR) antibody
preparations and then plaque-assayed on BHK-21 cells. Nil, No antibody. The data are representative of three experiments.
mAbs 2C10, 10C11 and 2H4 all gave equivalent results. (c) Equivalent antibody preparations were used to stain by ﬂow
cytometry the surfaces of MHV-68-infected (2 p.f.u. per cell, 18 h) BHK-21 cells.
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in vivo may be distinct qualitatively as well as quantitatively
from those for reducing infectivity in vitro. For example,
blocking major receptor-binding interactions might make
infection slower, but there is no particular reason to
believe that time limits infection in vivo. Herpesviruses
encode multiple cell-binding glycoproteins, and even
heparan sulfate binding might be sufﬁcient for endocytosis
(Fuki et al., 2000). Furthermore, the expression of
immunoglobulin Fc receptors on mucosal surfaces in vivo
(Spiekermann et al., 2002) may allow virions incapable of
cell binding still to infect via Fc receptor-mediated
endocytosis. Direct in vivo neutralization tests therefore
provide a crucial reality check for in vitro infectivity
reductions.
As gB-directed neutralization acted close to the obligate
infection step of viral membrane fusion, an alternative entry
pathway seemed unlikely. The infectivity preserved with gB-
directed neutralization probably reﬂected an appreciable
chance of fusion occurring, even when every mAb binding
site was occupied. One possibility is that not every gB
molecule on virions was accessible. The MHV-68 gB N
terminus–likethatofseveralothergammaherpesviruses–is
predicted to be heavily O-glycosylated, with nine potential
glycan attachment sites in the ﬁrst 30 aa alone. We have
previouslydocumentedquitevariableO-glycosylationofthe
MHV-68 ORF28 gene product (May et al., 2005c). There
may be similar heterogeneity in O-glycosylation near the gB
N terminus, such that some gBs are bound poorly by
antibody. Transformed cell lines cannot be considered
representative of natural glycosylation, but MHV-68
propagated in vivo showed at least as much resistance to
gB-directed neutralization as did that propagated in BHK-
21 cells (Fig. 6b). Such a limitation might also apply to the
N-terminal RGD neutralization target on the KSHV gB
(Akula et al., 2002).
Alternatively, antibody-bound gBs may still retain an
appreciable chance of participating in fusion, given the
right cellular setting. MHV-68 infects both ﬁbroblasts (Gill
et al., 2006) and epithelial cells (data not shown) via
endocytosis, so any antibody blocking membrane fusion
must remain attached in endosomes. Analogy with other
viruses would suggest that MHV-68 membrane fusion
results from energetically favourable conformational
changesinviralglycoproteinsatendosomalpH–essentially,
viruses tap the cellular energy invested in endosomal
acidiﬁcation to drive membrane fusion. If the more
mobile regions of viral fusion proteins are inaccessible, it
may be difﬁcult for antibodies to bind their targets strongly
enough to block pH-driven conformation changes com-
pletely. The high avidity of IgM pentamers – which should
be maintained in the oxidizing redox potential of endo-
somes (Austin et al., 2005) – would allow them to compete
more effectively, and this may explain why the best gB-
speciﬁcneutralizingmAbwasanIgM.Competitionbetween
antibody binding and glycoprotein conformation switching
could also explain the differences in neutralization between
cell types – NMuMG cells providing an environment more
conducive to conformation changes than BHK-21 cells.
Whatever the mechanistic explanation, the key practical
point was that an NMuMG-like, susceptible target was
available for incoming, antibody-bound virions to infect
in vivo.
One way to overcome the difﬁculty of holding on to viral
glycoproteins in endosomes would be to block receptor
binding and thereby prevent endocytosis in the ﬁrst place.
This is probably the major mechanism by which mAbs
neutralize small RNA viruses. It may also be the major
mechanism by which immune sera neutralize herpesviruses
(Fig. 5c).However,asnotedabove,morerobustherpesvirus
neutralization is likely to be achieved by targeting viral
membranefusioninmultipleways.Encouragingly,combin-
ing gB-speciﬁc and gH/gL-speciﬁc mAbs was more effective
thanusingeitheralone(Fig. 6).Whatmustbeappreciatedis
that herpesviruses have evolved over millions of years to
protect themselves against neutralization, so overcoming
this protection is unlikely to be easy.
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